Safety outcomes of osimertinib versus placebo as consolidation therapy after definitive chemoradiotherapy (CRT) in adults with unresectable stage III EGFR-mutated non-small cell lung cancer (NSCLC), evaluated in the phase III LAURA trial.
Osimertinib demonstrated a manageable safety profile as consolidation therapy post-CRT; specific adverse event rates and discontinuation numbers are reported in the trial but were not fully extractable from the provided abstract metadata.
Full safety data tables and absolute adverse event rates are not available from the provided source text, limiting quantitative detail in this summary. The study population is restricted to EGFR-mutated NSCLC, limiting generalizability to EGFR wild-type disease.
Osimertinib consolidation after definitive CRT appears safe for unresectable stage III EGFR-mutated NSCLC; clinicians should review the full LAURA safety data when considering this approach for eligible patients.
Explore related topics
